QLI Stock Overview
Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China.
Qilian International Holding Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.40|
|52 Week High||US$4.99|
|52 Week Low||US$1.36|
|1 Month Change||-25.53%|
|3 Month Change||-31.03%|
|1 Year Change||-67.21%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-86.00%|
Recent News & Updates
We Think You Can Look Beyond Qilian International Holding Group's (NASDAQ:QLI) Lackluster Earnings
Shareholders appeared unconcerned with Qilian International Holding Group Limited's ( NASDAQ:QLI ) lackluster earnings...
Qilian International signs Gan Di Xin's exclusive distribution agreement
Qilian International Holding Group ([[QLI]] +2.0%) announces agency agreement with China's Henan Kangzhiyuan Pharmaceutical to boost the sales of Gan Di Xin medicine for the initial agreement term of 5 years, beginning April 22, 2021.The agreement signed through Qilian's subsidiary, Gansu Qilianshan, will see Kangzhiyuan acting as the exclusive sales agent for the distribution
|QLI||US Pharmaceuticals||US Market|
Return vs Industry: QLI underperformed the US Pharmaceuticals industry which returned 9.6% over the past year.
Return vs Market: QLI underperformed the US Market which returned -10.8% over the past year.
|QLI Average Weekly Movement||8.0%|
|Pharmaceuticals Industry Average Movement||10.8%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.4%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: QLI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: QLI's weekly volatility (8%) has been stable over the past year.
About the Company
Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications.
Qilian International Holding Group Fundamentals Summary
|QLI fundamental statistics|
Is QLI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|QLI income statement (TTM)|
|Cost of Revenue||US$51.46m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.088|
|Net Profit Margin||5.52%|
How did QLI perform over the long term?See historical performance and comparison
Is Qilian International Holding Group undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate QLI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate QLI's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: QLI is good value based on its PE Ratio (15.9x) compared to the US Pharmaceuticals industry average (19.1x).
PE vs Market: QLI is poor value based on its PE Ratio (15.9x) compared to the US market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate QLI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: QLI is good value based on its PB Ratio (0.9x) compared to the US Pharmaceuticals industry average (1.6x).
How is Qilian International Holding Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Qilian International Holding Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Qilian International Holding Group performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QLI has high quality earnings.
Growing Profit Margin: QLI's current net profit margins (5.5%) are lower than last year (10.1%).
Past Earnings Growth Analysis
Earnings Trend: QLI's earnings have declined by 3.9% per year over the past 5 years.
Accelerating Growth: QLI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: QLI had negative earnings growth (-37.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.9%).
Return on Equity
High ROE: QLI's Return on Equity (5.5%) is considered low.
How is Qilian International Holding Group's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: QLI's short term assets ($40.4M) exceed its short term liabilities ($18.2M).
Long Term Liabilities: QLI's short term assets ($40.4M) exceed its long term liabilities ($509.9K).
Debt to Equity History and Analysis
Debt Level: QLI has more cash than its total debt.
Reducing Debt: Insufficient data to determine if QLI's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: QLI's debt is not well covered by operating cash flow (4.4%).
Interest Coverage: QLI earns more interest than it pays, so coverage of interest payments is not a concern.
What is Qilian International Holding Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QLI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QLI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as QLI has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Zhanchang Xin (54 yo)
Mr. Zhanchang Xin has been Chairman of the Board, President and Chief Executive Officer of Qilian International Holding Group Ltd. since incorporation and served as its Acting Principal Financial Officer....
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Zhanchang's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Zhanchang's compensation has been consistent with company performance over the past year.
Experienced Board: QLI's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Qilian International Holding Group Limited's employee growth, exchange listings and data sources
- Name: Qilian International Holding Group Limited
- Ticker: QLI
- Exchange: NasdaqGM
- Founded: 2019
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$50.050m
- Shares outstanding: 35.75m
- Website: https://www.qlsyy.net
Number of Employees
- Qilian International Holding Group Limited
- Jiuquan Eco & Tech Dev Zn
- Gansu Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/12 00:00|
|End of Day Share Price||2022/05/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.